BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required an intact host immune system. Genome-wide analysis of the BETi-induced transcriptional...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogg, Simon J., Vervoort, Stephin J., Deswal, Sumit, Ott, Christopher J., Li, Jason, Cluse, Leonie A., Beavis, Paul A., Darcy, Phillip K., Martin, Benjamin P., Spencer, Andrew, Traunbauer, Anna K., Sadovnik, Irina, Bauer, Karin, Valent, Peter, Bradner, James E., Zuber, Johannes, Shortt, Jake, Johnstone, Ricky W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340981/
https://www.ncbi.nlm.nih.gov/pubmed/28249162
http://dx.doi.org/10.1016/j.celrep.2017.02.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340981/
https://www.ncbi.nlm.nih.gov/pubmed/28249162
http://dx.doi.org/10.1016/j.celrep.2017.02.011

Ejemplares similares